Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

ImmunGene’s Pipeline of Next Generation Cancer Therapeutics Featured in BioWorld Today

November 11, 2010 By Bio-Medicine.Org

THOUSAND OAKS, Calif., Nov. 11, 2010 /PRNewswire/ — ImmunGene,
Inc., a privately held drug development company focused on targeted
antibody therapeutics with numerous anti-cancer functions built
into a single therapy, announced today that a profile of the
company and its pipeline is featured in the November 21 issue of
BioWorld Today in the NewCo section http://www.bioworld.com/.

The publication noted that, “ImmunGene is currently in advanced
partnership discussion with several biotech and pharma companies
for its payload… The firm’s approach involves fusing a monoclonal
antibody with a cytokine, initially interferon, for local delivery
to the tumor. Called a CmAb, the molecule can be aimed ‘directly
where we want it to go,’ (CEO Sanjay) Khare said.”

The addition of the cytokine means that: “‘…our CmAbs can do
more [than other antibody arming ADCs] since select cytokines are
associated with several desirable anti-tumor functions,’ he said.
CmAbs also are genetically engineered molecules, which could make
them simpler and cheaper to produce. ‘There’s no multistep
manufacturing process,’ Khare added.”

“Another benefit is that the CmAbs can be dosed at a very low
level and still be efficacious. ImmunGene’s researchers, for
example, have been able to limit interferon activity in CmAb to
one-one hundredth of the unfused IFN. By fusing it with an antibody
that binds only to tumor cells, that interferon dose is sufficient
to initiate cell death. ImmunGene’s lead CmAb candidate, IGN002, is
a third-generation antibody-fusion drug designed to target
CD20-positive tumors, initially going after non-Hodgkin’s lymphoma
not treatable by Rituxan (rituximab, Genentech Inc./Roche AG and
Biogen Idec Inc.),” noted the BioWorld article.

Dr. Sanjay Khare, ImmunGene’s Chief Executive Officer said, “We
are pleased to receive recognition from a global biotech
publication for ImmunGene’s pipeline of next genera

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech